Risk of Endocrine Complications in Cancer Patients Treated with Immune Check Point Inhibitors: A Meta-Analysis

10.2147/PGPM.S53163

10.1056/NEJMoa1003466

10.1056/NEJMoa1104621

10.1056/NEJMoa1305133

10.1158/1078-0432.CCR-07-4079

10.1200/JCO.2012.48.3685

10.1056/NEJMoa1200694

10.1016/S1470-2045(13)70551-5

10.1210/jc.2012-4075

10.1530/EJE-13-0434

10.1016/j.clineuro.2014.06.011

10.1158/1078-0432.CCR-14-2353

Beer TM , LogothetisC, GerritsenWRet al. Characterization of immune-related adverse events (iraes) in a Phase 3 trial of ipilimumab (IPI) versus placebo (PBO) in post-docetaxel MCRPC. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting 2014. Chicago, IL, USA, 30 May–3 June 2014.

Rodrigues BT , OttyZ, SanglaK, ShenoyVV. Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions. Endocrinol. Diabetes Metab. Case Rep.2014, 140098 (2014).

10.1530/EJE-14-0845

10.1126/scitranslmed.3008002

10.7326/0003-4819-151-4-200908180-00135

10.1016/0197-2456(86)90046-2

10.1136/bmj.327.7414.557

10.1016/S1470-2045(15)70122-1

10.1200/JCO.2011.38.4032

10.1200/JCO.2012.44.6112

10.1056/NEJMoa1412082

10.1016/S1470-2045(14)70189-5

10.1056/NEJMoa1504627

10.1016/S1470-2045(15)70076-8

10.1016/S1470-2045(15)00083-2

10.1189/jlb.1212621

10.4049/jimmunol.157.11.4762

10.1056/NEJMoa1200690

10.1016/j.critrevonc.2015.08.015

10.2217/fon.15.118

10.1586/14737140.2014.929501

Kust D , PrpićM, MurgićJet al. Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy. Anticancer Res.34(6), 3177–3184 (2014).

10.1158/2326-6066.CIR-13-0146

10.1210/jc.2014-2306

10.2214/AJR.10.6198

10.1055/s-0033-1355337

10.1158/2326-6066.CIR-14-0217

10.1056/NEJMoa1503093

10.1056/NEJMoa1414428

10.1056/NEJMoa1504030

Van Zuuren EJ , AlbustaAY, FedorowiczZ, CarterB, PijlH. Selenium supplementation for Hashimoto’s thyroiditis. Cochrane Database Syst. Rev. (6), CD010223 (2013).